Search Results for "lisdexamfetamine dimesylate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for lisdexamfetamine dimesylate. Results 11 to 15 of 15 total matches.

ThermaClear for Acne

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 2007  (Issue 1263)
and Therapeutics Coming Soon in The Medical Letter: Lisdexamfetamine dimesylate (Vyvanse) for ADHD Arformoterol ...
The FDA has approved ThermaClear (Therative), a battery-powered, handheld device, to treat individual acne lesions with heat. ThermaClear is indicated only for use on mild to moderate inflammatory acne, not severe nodular or severe cystic acne, and it is not meant to be used on blackheads and whiteheads. Two similar devices are already on the market: Zeno, another handheld device that delivers heat to acne lesions, and the Radiancy Clear Touch Lite Acne Clearance System, a larger heat-delivery device.
Med Lett Drugs Ther. 2007 Jun 18;49(1263):51-2 |  Show IntroductionHide Introduction

MoviPrep: A New Bowel Prep for Colonoscopy

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
and Therapeutics Coming Soon in The Medical Letter: Treatment of Lyme Disease Lisdexamfetamine dimesylate ...
MoviPrep (Salix) is a new polyethylene glycol (PEG)-based bowel cleansing preparation approved for use in adults prior to colonoscopy. It contains ascorbic acid, which acts as an additional cathartic and flavoring agent, and requires a lower volume of fluid (3 L compared to the traditional 4 L) than most other PEG products. HalfLytely is an FDA-approved 2-L PEG product, but it must be taken with bisacodyl.
Med Lett Drugs Ther. 2007 Jun 4;49(1262):47-8 |  Show IntroductionHide Introduction

Sitagliptin/Metformin (Janumet) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
and Therapeutics Coming Soon in The Medical Letter: Treatment of Lyme Disease Lisdexamfetamine dimesylate ...
Sitagliptin (Januvia) and metformin (Glucophage, and others) are now available in a single tablet (Janumet - Merck) for treatment of type 2 diabetes. The combination is approved by the FDA for use in patients not adequately controlled by sitagliptin or meformin alone or in those already taking both drugs. Metformin is also available in combination with the thiazolidinediones pioglitazone and rosiglitazone and with the sulfonylureas glipizide and glyburide.
Med Lett Drugs Ther. 2007 Jun 4;49(1262):45-7 |  Show IntroductionHide Introduction

Resperate for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007  (Issue 1264)
and Therapeutics Coming Soon in The Medical Letter: Lisdexamfetamine dimesylate (Vyvanse) for ADHD Lybrel ...
The FDA has approved the marketing of Resperate (InterCure), a device that helps patients breathe slowly, as an adjunct for treatment of hypertension. The FDA does not require proof of effectiveness for approval of devices with minimal potential for harm, such as this one.
Med Lett Drugs Ther. 2007 Jul 2;49(1264):55-6 |  Show IntroductionHide Introduction

Arformoterol (Brovana) for COPD

   
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007  (Issue 1264)
and Therapeutics Coming Soon in The Medical Letter: Lisdexamfetamine dimesylate (Vyvanse) for ADHD Lybrel ...
Arformoterol tartrate (Brovana - Sepracor), a singleisomer, long-acting beta2-agonist, has been approved by the FDA as an inhalation solution for nebulization for treatment of bronchoconstriction pulmonary disease (COPD). Arformoterol is the (R,R)-enantiomer of formoterol (Foradil), which is available as a powder for inhalation and was recently also approved as a solution for nebulization (Perforomist - Dey; available fall 2007)
Med Lett Drugs Ther. 2007 Jul 2;49(1264):53-5 |  Show IntroductionHide Introduction